Friday, October 9th 2015

SUBSCRIBE: RSS Feed for Spinal Cord Injury Zone Email Updates Follow Spinal Cord Injury Zone on Twitter Spinal Cord Injury Zone on Facebook

Articles Tagged: Clinical Trial

A shattering crash, an online chronicle, and an unexpected twist

Published: August 21, 2015 | Category: News | Spinal Cord Injury:

Jesi Stracham with her dogIn the age of social media, patients who test experimental treatments wield surprising clout.

The tweets and the selfies, the uploaded video clips, felt like a natural way for Jesi Stracham to record her halting progress as she fought to recover from a motorcycle accident that had left her paralyzed from the chest down.

She had no idea, as she tapped away at her iPhone from her hospital bed, what her bubbly posts would unleash. Continue Reading »

Regenerating nerve tissue in spinal cord injuries

Published: August 13, 2015 | Category: News

Rush-University-Medical-CenterRush begins participation in novel study using stem cells to treat spinal cord injuries

Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.

The therapy uses a population of cells derived from human embryonic stem cells containing progenitor cells that support nerve cells and can potentially make poorly functioning nerves function better. Continue Reading »

Olfactory cells transplanted to treat spinal cord injury

Published: June 19, 2015 | Category: News

Three years after they treated patients with spinal cord injury in a randomized clinical trial with transplanted cells from the patients’ olfactory mucosa (nasal cavities) to build a ‘bridge’ to span the gap between the damaged ends of the spinal cord, researchers found that some recipients had experienced a range of modest improvements and determined that the use of olfactory mucosa lamina propria (OLP) transplants was ‘promising and safe.’ Continue Reading »

‘Exciting’ progress for spinal injury drug

Published: June 12, 2015 | Category: News

Anthony FaingaaPioneers in the field of neurological therapy want paramedics to be armed with a breakthrough drug to quickly stop the damage spreading.

It’s the latest stage in the development of a project which started in 2011 at the University of Auckland.

The potential to carry the drug in the back of ambulances follows trials on rodents. Those tests confirmed a dose of peptide medicine could be administered into people’s veins, instead of straight to the spinal cord. Continue Reading »

India to participate in first clinical study trial to treat spinal cord injury using stem cells

Published: May 11, 2015 | Category: News

392-320x240By involving 18 patients, India will soon become a part of a first-of-its-kind clinical trial, a collaborative study conducted in China, Norway and America, involving 240 patients for treating spinal cord injury in humans through stem-cells.

India will be a part of a first-of-its-kind clinical trial, for treating spinal cord injury in humans through stem-cells. India will a part of the collaborative study conducted in China, Norway and America involving 240 patients led by China-based stem cell researcher Dr Wise Young. Continue Reading »

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Published: March 5, 2015 | Category: News

ast_opc1Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation’s top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

The Phase 1/2a trial follows the successful completion of the Phase 1 trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic SCI. Continue Reading »

Stem cells from human embryos prove safe, improve vision -study

Published: October 14, 2014 | Category: News

(Reuters) – The longest-running trial of stem cells derived from a human embryo found that the cells caused patients none of the problems scientists feared, such as forming tumors, and reversed partial blindness in about half the eyes receiving transplants, researchers reported on Tuesday. Continue Reading »

ISU clinical trial hopes to aid paralyzed dogs

Published: October 11, 2014 | Category: News

DaisyVeterinarians at Iowa State University are hoping to give 60 dogs a second chance at walking.

The university’s clinical trial for paralyzed dogs is testing a new drug that could potentially help more dogs overcome severe spinal cord injuries.

The trial is run by Dr. Nick Jeffery and Dr. Hilary Hu with ISU’s Veterinary Medical Center, and the team began recruiting for their trial in January. The trial will be using the test drug chondroitinase, an enzyme which helps to dissolve scar tissue around the dog’s injury. Continue Reading »

StemCells Inc. Initiates Phase 2 Clinical Trial In Cervical Spinal Cord Injury

Published: October 7, 2014 | Category: News

stemcellsinc-logoNEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI). Approximately 1.3 million people in the United States report being paralyzed due to an SCI, and there currently are no effective treatments available. Approximately 56% of the spinal cord injuries occur in the cervical region. Overall, approximately 13% of SCI patients have no mobility and 35% have limited mobility after the traumatic injury. Continue Reading »

Clinical trial will target spinal-cord injuries

Published: September 15, 2014 | Category: News

health-newsThe University of Arizona Medical Center is the site of a two-year clinical trial for a drug that could help people with acute spinal-cord injuries.

Sixty trauma centers in the U.S., Canada and Europe will test the safety and efficacy of the investigational drug SUN13837, to determine whether it can protect and regenerate spinal nerves, UA Medical Center officials say.

The study is sponsored by Asubio Pharmaceuticals, Inc. Patients will be randomly assigned to receive either a placebo or SUN13837 within 12 hours of injury and then daily for 28 days. Continue Reading »